Insider Trading Alert - OFC, DSW, JAZZ, IT And N Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 13, 2013, 134 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $14.34 to $156,760,095.40.

Highlighted Stocks Traded by Insiders:

Corporate Office Properties (OFC) - FREE Research Report

Omega Healthcare Investors Inc who is Director at Corporate Office Properties bought 10,000 shares at $22.09 on Dec. 13, 2013. Following this transaction, the Director owned 11,798 shares meaning that the stake was reduced by 556.17% with the 10,000-share transaction.

The shares most recently traded at $21.95, down $0.14, or 0.64% since the insider transaction. Historical insider transactions for Corporate Office Properties go as follows:

  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 20,000

The average volume for Corporate Office Properties has been 583,500 shares per day over the past 30 days. Corporate Office Properties has a market cap of $2.0 billion and is part of the financial sector and real estate industry. Shares are down 10.37% year-to-date as of the close of trading on Wednesday.

Corporate Office Properties Trust, a real estate investment trust (REIT), engages in the acquisition, development, ownership, management, and leasing of suburban office properties. The stock currently has a dividend yield of 4.91%. The company has a P/E ratio of 746.3. Currently there are 2 analysts that rate Corporate Office Properties a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OFC - FREE

TheStreet Quant Ratings rates Corporate Office Properties as a hold. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, compelling growth in net income and revenue growth. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full Corporate Office Properties Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

DSW (DSW) - FREE Research Report

Miller Philip B who is Director at DSW sold 1,000 shares at $43.12 on Dec. 13, 2013. Following this transaction, the Director owned 21,800 shares meaning that the stake was reduced by 4.39% with the 1,000-share transaction.

The shares most recently traded at $42.95, down $0.17, or 0.39% since the insider transaction. Historical insider transactions for DSW go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 3,994

The average volume for DSW has been 866,600 shares per day over the past 30 days. DSW has a market cap of $3.5 billion and is part of the services sector and retail industry. Shares are up 30.46% year-to-date as of the close of trading on Wednesday.

DSW Inc. operates as a branded footwear and accessories specialty retailer in the United States. The company offers fashion, shoes, dress, casual and athletic footwear, and accessories for women and men through its DSW stores and dsw.com. The stock currently has a dividend yield of 1.18%. The company has a P/E ratio of 26.1. Currently there are 2 analysts that rate DSW a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DSW - FREE

TheStreet Quant Ratings rates DSW as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full DSW Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Falberg Kathryn E who is EVP and CFO at Jazz Pharmaceuticals sold 3,000 shares at $120.50 on Dec. 13, 2013. Following this transaction, the EVP and CFO owned 128,721 shares meaning that the stake was reduced by 2.28% with the 3,000-share transaction.

The shares most recently traded at $115.39, down $5.11, or 4.43% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 47,208

The average volume for Jazz Pharmaceuticals has been 751,400 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $6.9 billion and is part of the health care sector and drugs industry. Shares are up 116.38% year-to-date as of the close of trading on Wednesday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company has a P/E ratio of 22.3. Currently there are 12 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Gartner (IT) - FREE Research Report

Sondergaard Peter who is SVP, Research at Gartner sold 3,059 shares at $65.54 on Dec. 13, 2013. Following this transaction, the SVP, Research owned 34,485 shares meaning that the stake was reduced by 8.15% with the 3,059-share transaction.

The shares most recently traded at $66.21, up $0.67, or 1.01% since the insider transaction. Historical insider transactions for Gartner go as follows:

  • 4-Week # shares sold: 131,444
  • 12-Week # shares sold: 198,557
  • 24-Week # shares sold: 201,557

The average volume for Gartner has been 443,900 shares per day over the past 30 days. Gartner has a market cap of $6.1 billion and is part of the technology sector and computer software & services industry. Shares are up 43.05% year-to-date as of the close of trading on Wednesday.

Gartner, Inc. provides independent and objective research and analysis on information technology (IT), computer hardware, software, communications, and related technology industries. The company has a P/E ratio of 34.8. Currently there are 4 analysts that rate Gartner a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IT - FREE

TheStreet Quant Ratings rates Gartner as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Gartner Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NetSuite (N) - FREE Research Report

Solomon Douglas P. who is SVP, General Counsel & Sec. at NetSuite sold 200 shares at $97.71 on Dec. 13, 2013. Following this transaction, the SVP, General Counsel & Sec. owned 21,257 shares meaning that the stake was reduced by 0.93% with the 200-share transaction.

Gill Ronald S who is Chief Financial Officer at NetSuite sold 3,090 shares at $96.91 on Dec. 13, 2013. Following this transaction, the Chief Financial Officer owned 37,820 shares meaning that the stake was reduced by 7.55% with the 3,090-share transaction.

The shares most recently traded at $94.13, down $2.78, or 2.95% since the insider transaction. Historical insider transactions for NetSuite go as follows:

  • 4-Week # shares sold: 37,593
  • 12-Week # shares sold: 94,030
  • 24-Week # shares sold: 150,407

The average volume for NetSuite has been 400,100 shares per day over the past 30 days. NetSuite has a market cap of $7.3 billion and is part of the technology sector and computer software & services industry. Shares are up 43.16% year-to-date as of the close of trading on Wednesday.

NetSuite Inc. provides cloud-based financials/enterprise resource planning (ERP) software suites in the United States and internationally. Currently there are 6 analysts that rate NetSuite a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on N - FREE

TheStreet Quant Ratings rates NetSuite as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full NetSuite Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tuesday: OHAI, AHT, OFC

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tuesday: OHAI, AHT, OFC

Insider Trading Alert - OFC, BURL And WM Traded By Insiders

Insider Trading Alert - OFC, BURL And WM Traded By Insiders

3 Hold-Rated Dividend Stocks: OFC, WDC, RDS.B

3 Hold-Rated Dividend Stocks: OFC, WDC, RDS.B

Insider Trading Alert - USCR, OFC And EPAY Traded By Insiders

Insider Trading Alert - USCR, OFC And EPAY Traded By Insiders

Insider Trading Alert - PFSI, GEVO And OFC Traded By Insiders

Insider Trading Alert - PFSI, GEVO And OFC Traded By Insiders